Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 8/2018

01-08-2018 | Review

Recent advances in tuberculosis diagnostics in resource-limited settings

Authors: Mitsuko Seki, Chang-Ki Kim, Satoshi Hayakawa, Satoshi Mitarai

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 8/2018

Login to get access

Abstract

Smear-negative and drug-resistant cases of tuberculosis (TB) disease necessitate the development of new diagnostic methods, especially in resource-limited settings. To improve the current TB situations, sensitive and specific TB point-of-care tests (POCTs) should be developed. This review addresses the current status of TB, novel diagnostic methodologies for TB, and the impact of those new diagnostics on TB control in such situations. Moreover, the perspective of TB management based on laboratory examinations is described. Smear microscopy with sputum samples is the only laboratory examination available in many resource-limited settings and is still used globally. Several nucleic acid amplification tests (NATs) have been developed. The World Health Organization (WHO) endorsed novel diagnostics based on NATs and updated their definition of a bacteriologically confirmed case requiring the biological specimen to be positive by smear microscopy, culture, or the WHO-recommended rapid diagnostic protocols. The use of new diagnostics increased the number of bacteriologically confirmed TB cases. Novel diagnostics are now available, but their sensitivity is still lower than that of conventional liquid culture method. To address the increasing incidence of TB, more resources including novel diagnostics as POCTs with higher sensitivity must be allocated to healthcare systems.
Literature
1.
go back to reference WHO (2017) Global tuberculosis report 2017. WHO, Geneva WHO (2017) Global tuberculosis report 2017. WHO, Geneva
2.
go back to reference WHO (2012) Assessing tuberculosis under-reporting through inventory studies. In: WHO (ed) WHO (2012) Assessing tuberculosis under-reporting through inventory studies. In: WHO (ed)
4.
go back to reference WHO (2016) Global tuberculosis report 2016. WHO, Geneva WHO (2016) Global tuberculosis report 2016. WHO, Geneva
5.
go back to reference CLSI (2008) Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A., vol 28. Clinical and Laboratory Standards Institute, Wayne CLSI (2008) Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A., vol 28. Clinical and Laboratory Standards Institute, Wayne
7.
go back to reference WHO (2011) Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement, Geneva WHO (2011) Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis: policy statement, Geneva
8.
go back to reference Ridderhof JC, van Deun A, Kam KM, Narayanan PR, Aziz MA (2007) Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ 85(5):354–359CrossRefPubMedPubMedCentral Ridderhof JC, van Deun A, Kam KM, Narayanan PR, Aziz MA (2007) Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ 85(5):354–359CrossRefPubMedPubMedCentral
9.
go back to reference Hall L, Jude KP, Clark SL, Wengenack NL (2011) Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex for first and second line drugs by broth dilution in a microtiter plate format. J Vis Exp (52). https://doi.org/10.3791/3094 Hall L, Jude KP, Clark SL, Wengenack NL (2011) Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex for first and second line drugs by broth dilution in a microtiter plate format. J Vis Exp (52). https://​doi.​org/​10.​3791/​3094
10.
go back to reference Ratnam S, March SB (1986) Effect of relative centrifugal force and centrifugation time on sedimentation of mycobacteria in clinical specimens. J Clin Microbiol 23(3):582–585PubMedPubMedCentral Ratnam S, March SB (1986) Effect of relative centrifugal force and centrifugation time on sedimentation of mycobacteria in clinical specimens. J Clin Microbiol 23(3):582–585PubMedPubMedCentral
11.
go back to reference Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K, Ushio R, Ikeda M, Sakamaki K, Yoshiyama T, Kaneko T (2015) Sensitivity and specificity of Cobas TaqMan MTB real-time polymerase chain reaction for culture-proven Mycobacterium tuberculosis: meta-analysis of 26999 specimens from 17 studies. Sci Rep 5:18113. https://doi.org/10.1038/srep18113 CrossRefPubMedPubMedCentral Horita N, Yamamoto M, Sato T, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K, Ushio R, Ikeda M, Sakamaki K, Yoshiyama T, Kaneko T (2015) Sensitivity and specificity of Cobas TaqMan MTB real-time polymerase chain reaction for culture-proven Mycobacterium tuberculosis: meta-analysis of 26999 specimens from 17 studies. Sci Rep 5:18113. https://​doi.​org/​10.​1038/​srep18113 CrossRefPubMedPubMedCentral
13.
go back to reference WHO (2015) Global tuberculosis report 2015. WHO, Geneva WHO (2015) Global tuberculosis report 2015. WHO, Geneva
14.
go back to reference WHO (2014) Global tuberculosis report 2014. WHO, Geneva WHO (2014) Global tuberculosis report 2014. WHO, Geneva
15.
go back to reference WHO (2013) Global tuberculosis report 2013. WHO, Geneva WHO (2013) Global tuberculosis report 2013. WHO, Geneva
16.
go back to reference Initiative GL (2017) GLI planning for country transition to Xpert MTB/RIF Ultra cartridges Initiative GL (2017) GLI planning for country transition to Xpert MTB/RIF Ultra cartridges
17.
go back to reference FIND (2017) Report for WHO: a multicentre non-inferiority diagnostic accuracy study of the Ultra assay compared to the Xpert MTB/RIF assay, Geneva FIND (2017) Report for WHO: a multicentre non-inferiority diagnostic accuracy study of the Ultra assay compared to the Xpert MTB/RIF assay, Geneva
18.
go back to reference WHO (2016) The use of loop-mediated isothermal amplification ( TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. In: WHO (ed) WHO (2016) The use of loop-mediated isothermal amplification ( TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. In: WHO (ed)
19.
go back to reference Nagai K, Horita N, Yamamoto M, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nakashima K, Ushio R, Ikeda M, Narita A, Kanai A, Sato T, Kaneko T (2016) Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysis. Sci Rep 6:39090. https://doi.org/10.1038/srep39090 CrossRefPubMedPubMedCentral Nagai K, Horita N, Yamamoto M, Tsukahara T, Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nakashima K, Ushio R, Ikeda M, Narita A, Kanai A, Sato T, Kaneko T (2016) Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysis. Sci Rep 6:39090. https://​doi.​org/​10.​1038/​srep39090 CrossRefPubMedPubMedCentral
20.
go back to reference WHO (2015) The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. In: WHO (ed) WHO (2015) The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance. In: WHO (ed)
29.
go back to reference Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, team T-N (2014) Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383(9915):424–435. https://doi.org/10.1016/S0140-6736(13)62073-5 CrossRefPubMed Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, Bara W, Mungofa S, Pai M, Hoelscher M, Dowdy D, Pym A, Mwaba P, Mason P, Peter J, Dheda K, team T-N (2014) Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet 383(9915):424–435. https://​doi.​org/​10.​1016/​S0140-6736(13)62073-5 CrossRefPubMed
31.
go back to reference WHO (2003) Treatment of tuberculosis: guidelines for national programmes. In: WHO (ed) WHO (2003) Treatment of tuberculosis: guidelines for national programmes. In: WHO (ed)
32.
go back to reference WHO (2016) WHO treatment guidelines for drug-resistant tuberculosis—2016 update. In: WHO (ed) WHO (2016) WHO treatment guidelines for drug-resistant tuberculosis—2016 update. In: WHO (ed)
34.
go back to reference Kent PT, Kubica GP (1985) A guide for level III In: Laboratory public health mycobacteriology. Centers for Disease Control, US Dept of Public Health and Human Services, Atlanta, Ga, pp 31–56 Kent PT, Kubica GP (1985) A guide for level III In: Laboratory public health mycobacteriology. Centers for Disease Control, US Dept of Public Health and Human Services, Atlanta, Ga, pp 31–56
36.
Metadata
Title
Recent advances in tuberculosis diagnostics in resource-limited settings
Authors
Mitsuko Seki
Chang-Ki Kim
Satoshi Hayakawa
Satoshi Mitarai
Publication date
01-08-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 8/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3258-y

Other articles of this Issue 8/2018

European Journal of Clinical Microbiology & Infectious Diseases 8/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.